 SAN FRANCISCO, Nov. 13, 2020 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor BBP-398 in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes. BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Centers Therapeutics Discovery division. 